Apixaban News and Research

RSS
Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Application for regulatory approval of apixaban in Europe to be submitted

Application for regulatory approval of apixaban in Europe to be submitted

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Pfizer announces fiscal 2009 third-quarter results

Pfizer announces fiscal 2009 third-quarter results

New type of anti-clotting drug called Apixaban

New type of anti-clotting drug called Apixaban

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome